-17% and all-time low: Valbiotis share pays the price for abandoning its objectives
The stock of the La Rochelle-based laboratory suffers a heavy trading session following interim results whose publication is accompanied by a renunciation of several commercial ambitions. Two research firms responded immediately by lowering their targets while maintaining their buy ratings.
The company renounces its €3 million revenue target and withdraws its 2027 and 2030 ambitions
The stock fell 16.82% to €0.55, after touching €0.4860 during the session, a new all-time low that erases the previous record of €0.5261 from November 14, 2025. The decline is part of an already established trend: -30.51% over three months, and a price 38.31% below the 200-day moving average. Valbiotis published on Monday, October 12 interim accounts which show a net loss reduced to €3.4 million and cash reserves of €11.7 million following the June capital increase.
Commercial momentum continued in the third quarter "at a pace however below the Company's expectations". The group consequently renounces its ambition of €3 million in revenue for fiscal year 2026, a level that corresponded to the analyst consensus noted on October 6, and withdraws its targets for 2027 and 2030.
TP Icap Midcap and Portzamparc lower their target price by €0.50 each
The analyst consensus was revised the same day. TP Icap Midcap lowered its target from €1.80 to €1.30, and Portzamparc from €1.90 to €1.40. Both firms maintain a buy rating. Even after these reductions, their targets remain well above the current share price, with the gap amounting to more than 1.2 times the current level of the stock.
Find details on analyst opinions on Valbiotis. The Paris market remains moderately upward-oriented, with the CAC 40 rising 0.24% at midday, which bears no resemblance to the movement of the stock. On the technical side, the RSI at 43 remains neutral despite the magnitude of the fall. The support at €0.59 has given way and resistance is now much higher, at €0.81.
